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ObituaryBaruch Blumberg (1925–2011)‘‘It is clear that I could not have planned the investigation at the
beginning to ﬁnd the cause of hepatitis B. This experience does
not encourage an approach to basic research which is based
exclusively on speciﬁc goal-directed programs for the solution
of biological problems’’.
Nobel Lecture, December 13, 1976
The initial steps of a scientiﬁc career may teach more on the
process who leads a researcher to unanimously recognized dis-
coveries than any speculation on the chance he may have bene-
ﬁted. Born in 1925, Baruch Blumberg had the ﬁrst of his many
ﬁeld experiences in the late forties when, during his medical
studies, he went to Sumatra where he cared for a remote pluri-
ethnic population and became interested in the heterogeneous
response of this population to infection. ‘‘This experience was
recalled in later years when I became interested in the study of inher-
ited variations in susceptibility to disease’’ he said. Following a fel-
lowship in rheumatology, he joined the Oxford University
Department of Biochemistry where he did his PhD thesis on the
properties of hyaluronic acid. During this period, he was intro-
duced to the concept of polymorphism and began studying, in
various populations, inherited polymorphisms of serum proteins
in relation to disease. He followed this research line from 1957 to
1964 as head of the Geographic Medicine and Genetics Section at
NIH and, subsequently, created the Division of Clinical Research
of the Institute for Cancer Research (ICR) in Philadelphia where
he was appointed Professor of Medicine and Anthropology at
the University of Pennsylvania.
Performing ﬁeldwork all over the world, his research was
marked by an integrated pluridisciplinary approach, which was
reﬂected by the skills of members of his research group (notably
T. London, I. Millman, E. Lutsbader, and B. Werner) and his many
close collaborations with immunologists, virologists, clinicians,
pathologists, epidemiologists, and anthropologists.
Among the many outstanding scientists who deciphered the
unique molecular mysteries of HBV at Fox Chase ICR (retrovirus
in disguise, hepaDNA genus replication, cccDNA, etc.), one must
mention Jessie Summers, Bill Mason, Christoph Seeger, John Tai-
lor (HDV), without forgetting Bob Snyder who ﬁrst described the
HBV hepatocellular cancer model in woodchucks.
The year 1964 marked the beginning of his improbable hepa-
titis B saga. In the early 1960, he tested the hypothesis that
‘‘Patients who had received large numbers of transfusions might
develop antibodies against one or more of the polymorphic serum
proteins, which themselves had not inherited’’. By means of a simple
double gel diffusion technique, he and his group used the serum
of polytransfused patients to screen sera from many different
populations. In 1963, he observed a precipitin band between
the serum of a hemophilia patient from New York and that of
an Aborigine from Australia. He coined this presumed polymor-Journal of Hepatology 20phism ‘‘Australia Antigen’’ (Au), which showed wide geographical
distribution variations with higher frequency in patients with
leukemia or Down Syndrome. By early 1966, one of the trisomic
patients he was following up with E. Sutnick and W. London
turned Au-positive while originally Au-negative. ‘‘We did a series
of liver chemistry tests which showed that between the ﬁrst (nega-
tive for Au) and the second testing (positive for Au); the patient
had developed a form of anicteric hepatitis’’. Serendipitously, this
sequence also occurred in a lab technician. This initial publication
coauthored by Harvey Alter [1] who indeed had initially observed
the new antigen for the ﬁrst time generated much skepticism. But
the association between Au and hepatitis was soon conﬁrmed by
further studies especially from K. Okochi in Japan and A.M. Prince
in the US, who rightly associated it speciﬁcally with hepatitis B
only.
The consequences of this discovery were immediate and
immense. As early as 1969, blood banks worldwide began screen-
ing blood donors for Au (later on renamed HBsAg). In the late
1960s, K. Okochi demonstrated that transfused patients were
much less likely to develop post transfusion hepatitis if they
received an Au-positive unit and/or developed antibodies against
it (anti-HBs).
‘‘We presumed that the very large amount of HBsAg present in
the blood could be separated from any infectious particles and used
as an antigen to elicit the production of antibodies’’ which ‘‘in turn
would protect against infection by the virus’’. The revolutionary
concept of the ﬁrst generation hepatitis B ‘‘plasma vaccine’’ was
born, the ﬁrst ever antiviral vaccine which was not obtained via
in vitro cultivation. This paved the way, after the cloning of
HBV by P. Tiollais in Paris, to the development of the present
engineered recombinant vaccines now integrated worldwide in
the universal vaccine agenda for newborns. Blumberg’s group11 vol. 55 j 241–242
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also contributed to the development of serological tests, to the
description of the natural history of hepatitis B and of its geo-
graphical distribution, to the importance and ethical implications
of mother–child transmission in the spread of the HBV carrier
state, and ﬁnally, in collaboration with French and Senegalese
research groups, to its role in hepatocellular carcinoma. Many
more steps of his career would deserve to be mentioned. Last
but not least the well deserved Nobel Prize in Medicine in
1976. Those who knew him were not surprised when, in 1999,
he was appointed director of NASA’s Astrobiology Department,
looking for the origin of life. Still highly active, he died in Califor-
nia preparing for a lecture.
The driving energy, curiosity, and creativity describe at best
and in a few words, the distinctive nature of Barry Bloomberg,
the man, (for a while excellent squash player). Within his group
in the Department of Clinical research, he was always capable
of integrating, without partisanship, all specialties in a common
project of truly pluridisciplinary dimensions.
His group, in his image, was most welcoming and in the fre-
quent weekly ‘‘protocol’’ meetings, new ideas emerged, always
very innovating and even sometimes utopist and ultimately
wrong but amazingly creative. During his research visits in the
ﬁeld, occasionally quite exotic, he recognized the spirit of his
own work. He owed his humanity to his immense culture: liter-
ary as well as scientiﬁc and to his unique sense of humor.
When his intrusive landmark contributions in the closed ﬁeld
of leprosy were challenged by ‘‘the’’ experts, he ironized ‘‘We are
now lepers among lepers’’.242 Journal of Hepatology 201Reference
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